Skip to main content

Wedbush Remains a Buy on Neurocrine (NBIX)

Tipranks - Tipranks - Fri Feb 13, 8:18AM CST

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Neurocrine, with a price target of $151.00.

Valentine's Day Sale - 70% Off

Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, BioCryst, and Denali Therapeutics. According to TipRanks, Chico has an average return of 10.9% and a 51.31% success rate on recommended stocks.

In addition to Wedbush, Neurocrine also received a Buy from TipRanks – xAI’s xAi Drug Manufacturers – Specialty and Generic in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Neurocrine (NASDAQ: NBIX).

See today’s best-performing stocks on TipRanks >>

Based on Neurocrine’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $794.9 million and a net profit of $209.5 million. In comparison, last year the company earned a revenue of $622.1 million and had a net profit of $129.8 million

Read More on NBIX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).